Weight Loss Maintenance and Cellular Aging in the Supporting Health Through Nutrition and Exercise Study.
Weight Loss Maintenance and Cellular Aging in the Supporting Health Through Nutrition and Exercise Study.
复制标题
DOI：
10.1097/psy.0000000000000616
复制
发表时间：
2018-09
影响因子：
3.3
通讯作者：
Epel ES
中科院分区：
文献类型：
--
作者：
Mason AE;Hecht FM;Daubenmier JJ;Sbarra DA;Lin J;Moran PJ;Schleicher SG;Acree M;Prather AA;Epel ES
在肥胖症的减肥临床试验中，确定干预臂、体重变化和减肥维持对端粒长度（TL）的影响。BMI在30到45之间的成年人（N=194）被随机分配到一个5.5个月的减肥计划中，其中有（n=100）或没有（n=94）正念训练和相同的饮食运动指南。我们评估了基线和基线后3、6和12个月免疫细胞群（主要是外周血单核细胞[PBMC]，但也包括粒细胞和T及B淋巴细胞）的TL。我们将减肥维持定义为从干预前到干预后至少减轻5%或10%的体重（在单独的模型中进行测试），并在12个月时保持这种减轻。我们预测，更大的体重减轻和体重减轻的维持将与TL延长相关。无论是减肥干预显着预测TL的变化，也没有量的体重变化，在任何时间点。在所有受试者中，维持至少10%的体重减轻与较长的PBMC TL相关[B=239.08，95% CI（0.92，477.25），p= 0.049]，CD8+ TL [B=417.26，95% CI（58.95，775.57），p= 0.023]，粒细胞TL较长[B=191.56，95% CI（-4.23，387.35），p= 0.055]。在考虑基线TL后，体重减轻5%或更高的维持与12个月时PBMC TL更长相关（B=163.32，95% CI 4.00，320.62]，p=.045）。这些测试应根据多项测试的校正进行解释。在肥胖症患者中，减肥和保持体重减轻10%或以上可能会导致TL延长，这可能预示着免疫和代谢功能的改善。在这项研究中，TL延长的持续时间未知超过12个月，需要进一步研究。Clinicaltrials.gov标识符NCT 00960414;开放科学框架（OSF）预注册：https://osf.io/t3r2g/
To determine, within a weight-loss clinical trial for obesity, the impact of intervention arm, weight change, and weight-loss maintenance on telomere length (TL). Adults (N=194) with a BMI between 30 and 45 were randomized to a 5.5-month weight-loss program with (n=100) or without (n=94) mindfulness training and identical diet-exercise guidelines. We assessed TL at baseline and 3, 6, and 12 months post-baseline in immune cell populations (primarily in peripheral blood mononuclear cells [PBMCs], but also in granulocytes and T and B lymphocytes). We defined weight-loss maintenance as having lost at least 5% or 10% of body weight (tested in separate models) from pre- to post-intervention, and having maintained this loss at 12 months. We predicted that greater weight loss and weight-loss maintenance would be associated with TL lengthening. Neither weight-loss intervention significantly predicted TL change, nor did amount of weight change, at any timepoint. Across all participants, weight-loss maintenance of at least 10% was associated with longer PBMC TL [b=239.08, 95% CI (0.92, 477.25), p=.049], CD8+ TL [b=417.26, 95% CI (58.95, 775.57), p=.023], and longer granulocyte TL [b=191.56, 95% CI (-4.23, 387.35), p=.055] at 12 months after accounting for baseline TL. Weight-loss maintenance of 5% or greater was associated with longer PBMC TL (b=163.32, 95% CI 4.00, 320.62], p=.045) at 12 months after accounting for baseline TL. These tests should be interpreted in light of corrections for multiple tests. Among individuals with obesity, losing and maintaining a weight loss of 10% or greater may lead to TL lengthening, which may portend improved immune and metabolic function. TL lengthening in this study is of unknown duration beyond 12 months, and requires further study. Clinicaltrials.gov identifier NCT00960414; Open Science Framework (OSF) preregistration: https://osf.io/t3r2g/